Popular Articles From: Mart Resources, Inc.: UMU-13 Initial Flow Test Results, Drilling Update, and Dividend Update to Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0986923001&sourceType=1 http://www.ccnmatthews.com/logos2/223mmt.jpg CALGARY, ALBERTA --
Sign-up for Mart Resources, Inc.: UMU-13 Initial Flow Test Results, Drilling Update, and Dividend Update investment picks
-- Domino Foods, Inc. will serve as sponsor NEW YORK , Jan.
Sign-up for Martha Bakes To Premiere Fourth Season On PBS Beginning January 10th investment picks
Marvell's ARMADA Mobile PXA1802 5-mode 4G LTE modem is at the core of Meizu's Flagship MX4 Pro Premium Smartphone, now available for more than one billion of combined subscribers of China Mobile and China Unicom SANTA CLARA, Calif.
Sign-up for Meizu Launches Its Flagship MX4 Pro Premium 4G LTE Smartphone for China Mobile and China Unicom Powered by Marvell's ARMADA Mobile 5-mode 4G LTE Solution investment picks
Marvell's AP3200 Reference Platform combines award-winning ARMADA and Avastar product lines and integrates dual concurrent 802.11 radios (4x4 802.11ac Wave-2 with 160MHz support and Multi-User, Multiple Input and Multiple Output (MU-MIMO) and 4x4 802.11n with 256 QAM support) for next-generation enterprise and home connectivity applications SANTA CLARA, Calif.
Sign-up for Marvell Introduces Industry's Highest Performance 4x4 802.11ac Wave-2 Wi-Fi and System-on-Chip Platform for Enterprise Access Point and Smart Home Gateway Solutions investment picks
Matador Resources Company (NYSE: MTDR) (“Matador” or the “Company”), an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources, with an emphasis on oil and natural gas shale and other unconventional plays and with a current focus on its Eagle Ford operations in South Texas and its Permian Basin operations in Southeast New Mexico and West Texas, today announced plans to host a live conference call on Tuesday, December 9, 2014 at 9:00 a.m. CST to outline its plans for next year and provide an update on this quarter’s activities.
Sign-up for Matador Resources Company Announces Plans to Host Conference Call on Tuesday, December 9, 2014 investment picks
Department of Energy Funded Program Supports Energy Storage Technology Innovation SAN DIEGO , Nov.
Sign-up for Maxwell Technologies Awarded U.S. Advanced Battery Consortium Contract to Develop High-Performance Hybrid Ultracapacitor/Lithium-ion Battery for Stop-Start Autos investment picks
http://media.marketwire.com/attachments/201409/79135_m.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158341&ProfileId=051205&sourceType=1 OAK BROOK, IL --
Sign-up for McDonald's to Enter New Market of Kazakhstan in 2015 investment picks
Montana-Dakota Utilities Co., a division of MDU Resources Group (NYSE:MDU) announced today that it has signed an agreement to purchase a North Dakota wind farm to be developed by ALLETE Clean Energy, a subsidiary of ALLETE, Inc. (NYSE:ALE). The wind project, located near Hettinger, N.D., and comprised of 43 turbines producing 107.5 megawatts of electricity, is anticipated to be completed in December 2015.
Sign-up for Montana-Dakota Utilities Signs Agreement to Purchase North Dakota Wind Farm investment picks
The Kentucky Board of Medical Imaging and Radiation Therapy (KBMIRT) has released two new online services, offering both professionals and citizens increased access to licensee information and a more convenient license renewal process.
Sign-up for The Kentucky Board of Medical Imaging and Radiation Therapy Releases Two New Online Services investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0976690001&sourceType=1 LAS VEGAS, NEVADA --
Sign-up for Medical Imaging Corp. Acquires 3 Imaging Centers and Raises $2 Million investment picks
Leading Weight-Management Company Tackles Long-Term Wellness with Thrive by Medifast™ and Optimal Health by Take Shape For Life™ Launches OWINGS MILLS, Md.
Sign-up for Medifast Launches New Healthy Living Program and Product Lines investment picks
http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153765&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and YAVNE, ISRAEL --
Sign-up for Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology investment picks
SAN DIEGO , Dec.
Sign-up for MEI Pharma Announces Pricing Of Public Offering Of Common Stock investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov.
Sign-up for New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy.
Sign-up for Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec.
Sign-up for Merck Begins Tender Offer to Acquire Cubist investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.
Sign-up for Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.
Sign-up for Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Popular Articles From: Mart Resources, Inc.: UMU-13 Initial Flow Test Results, Drilling Update, and Dividend Update to Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent